AstraZeneca/Merck Reinforce Lynparza’s Prostate Cancer Position With First-Line Data

 
• By Alaric DeArment

The companies published data showing the drug was effective in patients with both homologous recombinant repair mutated and non-mutated disease.

AstraZeneca and Merck are closer to snagging a first-line prostate cancer label for Lynparza • Source: Shutterstock

More from Anticancer

More from Therapy Areas